Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 8/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.51 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8656278 | 1.00 | LPAR1 (0.55) | LPAR1S1PR4S1PR1S1PR3S1PR2 | |
| SCHEMBL29758247 | 1.00 | LPAR1 (0.55) | LPAR1S1PR4S1PR1S1PR3S1PR2 | |
| SCHEMBL26908453 | 1.00 | LPAR1 (0.55) | LPAR1S1PR4S1PR1S1PR3S1PR2 | |
| SCHEMBL26908447 | 1.00 | LPAR1 (0.55) | LPAR1S1PR4S1PR1S1PR3S1PR2 | |
| SCHEMBL10459319 | 1.00 | LPAR1 (0.55) | LPAR1S1PR4S1PR1S1PR3S1PR2 | |
| SCHEMBL26908448 | 1.00 | LPAR1 (0.55) | LPAR1S1PR4S1PR1S1PR3S1PR2 | |
| SCHEMBL4943606 | 1.00 | LPAR1 (0.55) | LPAR1S1PR4S1PR1S1PR3S1PR2 | |
| SCHEMBL10533195 | 1.00 | LPAR1 (0.55) | LPAR1S1PR4S1PR1S1PR3S1PR2 | |
| SCHEMBL7692985 | 1.00 | LPAR1 (0.55) | LPAR1S1PR4S1PR1S1PR3S1PR2 | |
| SCHEMBL5552741 | 0.98 | L3MBTL1 (0.52) | LPAR1S1PR4S1PR1S1PR3S1PR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116075-A1 | SUBSTRATE, SELECTIVE FILM DEPOSITION METHOD, DEPOSITION FILM OF ORGANIC MATTER, AND ORGANIC MATTER | CENTRAL GLASS COMPANY, LIMITED (JP) | 2024-04-11 | — | — | US | disclosed |
| EP-4287240-A1 | SUBSTRATE, SELECTIVE FILM DEPOSITION METHOD, DEPOSITION FILM OF ORGANIC MATTER, AND ORGANIC MATTER | Central Glass Company, Limited (JP) | 2023-12-06 | — | — | EP | disclosed |
| CN-116685715-A | Substrate, selective film deposition method, deposited film of organic substance, and organic substance | 中央硝子株式会社 | 2023-09-01 | — | — | CN | disclosed |
| WO-2022163825-A1 | SUBSTRATE, SELECTIVE FILM DEPOSITION METHOD, DEPOSITION FILM OF ORGANIC MATTER, AND ORGANIC MATTER | セントラル硝子株式会社 | 2022-08-04 | — | — | WO | disclosed |
| US-8394356-B2 | Diagnostic imaging contrast agents with extended blood retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120107249-A1 | Diagnostic Imaging Contrast Agents with Extended Blood Retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8017105-B2 | Diagnostic imaging contrast agents with extended blood retention | LANTHEUS MEDICAL IMAGING, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-7229606-B2 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20070020185-A1 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. A DELAWARE CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070020184-A1 | Diagnostic imaging contrast agents with extended blood retention | EPIX PHARMACEUTICALS, INC. A DELAWARE CORPORATION | 2007-01-25 | — | — | US | disclosed |
| EP-1043982-B1 | LIPASE INHIBITING POLYMERS | GENZYME CORP (US) | 2005-11-09 | — | — | EP | disclosed |
| US-20040208827-A1 | MEDICAL DIAGNOSIS; examining vasculature of a tissue, obtains a NMR image; reducing renal and hepatocellular uptake, lost less from the bloodstream, use a lower doses, retained by the blood for a prolonged period of time | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040202613-A1 | Chelate compounds | EPIX MEDICAL, INC., A DELAWARE CORPORATION | 2004-10-14 | — | — | US | disclosed |
| US-6676929-B2 | MEDICAL DIAGNOSIS; GADOFOSVESET | EPIX MEDICAL, INC. | 2004-01-13 | — | — | US | disclosed |
| US-20030180223-A1 | Magnetic resonance imaging | LANTHEUS MEDICAL IMAGING, INC. | 2003-09-25 | — | — | US | disclosed |
| US-6572850-B1 | Treating obesity by administering a polyether substituted with a pendant B-lactone group;reduction in fat hydrolysis and absorption | GELTEX PHARMACEUTICALS, INC. | 2003-06-03 | — | — | US | disclosed |
| US-6558657-B1 | Synthetic polymer, carbohydrate or protein substituted with disulfide moiety that inhibits fat hydrolysis | GELTEX PHARMACEUTICALS, INC. | 2003-05-06 | — | — | US | disclosed |
| US-20020164289-A1 | Medical diagnosis | CITIZENS BANK, N.A. | 2002-11-07 | — | — | US | disclosed |
| EP-0806968-A2 | DIAGNOSTIC IMAGING CONTRAST AGENTS WITH EXTENDED BLOOD RETENTION | Epix Medical, Inc. (US) | 1997-11-19 | — | — | EP | disclosed |
| WO-1996023526-A2 | DIAGNOSTIC IMAGING CONTRAST AGENTS WITH EXTENDED BLOOD RETENTION | EPIX MEDICAL, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020164289-A1 | Medical diagnosis | FABP1, B2M, MB | LPAR1 3325/4885S1PR4 521/4885S1PR1 898/4885 |
| US-20030180223-A1 | Magnetic resonance imaging | BHMT, FABP1, FABP7 | LPAR1 2941/4885S1PR4 292/4885S1PR1 483/4885 |
| US-20040208827-A1 | MEDICAL DIAGNOSIS; examining vasculature of a tissue, obtains a NMR image; reducing renal and hepatocellular uptake, lost less from the bloodstream, use a lower doses, retained by the blood for a prolonged period of time | FABP1, BHMT, FABP3 | LPAR1 3129/4885S1PR4 574/4885S1PR1 952/4885 |
| US-20070020185-A1 | Diagnostic imaging contrast agents with extended blood retention | FABP1, B2M, BHMT | LPAR1 2722/4885S1PR4 325/4885S1PR1 553/4885 |
| US-20120107249-A1 | Diagnostic Imaging Contrast Agents with Extended Blood Retention | FABP1, B2M, BHMT | LPAR1 2722/4885S1PR4 325/4885S1PR1 553/4885 |
| US-20040202613-A1 | Chelate compounds | FABP1, BHMT, FABP3 | LPAR1 3713/4885S1PR4 650/4885S1PR1 1043/4885 |
| US-20070020184-A1 | Diagnostic imaging contrast agents with extended blood retention | FABP1, B2M, BHMT | LPAR1 2722/4885S1PR4 325/4885S1PR1 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.